Lantheus Holdings, Inc. $LNTH Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 53.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 306,723 shares of the medical equipment provider’s stock after selling 352,581 shares during the period. BNP Paribas Financial Markets owned approximately 0.46% of Lantheus worth $20,412,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC boosted its position in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 698 shares during the period. First Trust Advisors LP boosted its position in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after buying an additional 19,008 shares during the period. Baird Financial Group Inc. boosted its position in shares of Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after buying an additional 500 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of Lantheus by 88.1% during the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after buying an additional 1,591 shares during the period. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Lantheus during the second quarter worth $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of several research analyst reports. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. The Goldman Sachs Group restated a “neutral” rating and set a $94.00 price target on shares of Lantheus in a research report on Thursday, May 7th. Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. William Blair restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, March 17th. Finally, Jefferies Financial Group restated a “buy” rating and set a $110.00 price target on shares of Lantheus in a research report on Tuesday, March 17th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $101.86.

Lantheus Trading Down 1.8%

NASDAQ:LNTH opened at $100.98 on Friday. The firm has a market cap of $6.57 billion, a PE ratio of 24.33 and a beta of -0.03. The stock has a fifty day moving average price of $88.01 and a 200 day moving average price of $74.96. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $104.00. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.Lantheus’s revenue was up 1.2% compared to the same quarter last year. During the same period last year, the business posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.